Help End AIDS Together: Working Toward Vaccine and Cure for HIV/AIDS

Date: Monday, 27 October
Time: 14:30 – 16:30
Venue: CTICC Room 1.63 – 1.64 

Hosting partners: 
     International AIDS Vaccine Initiative (IAVI)
     International AIDS Society Towards an HIV Cure Initiative

Linda-Gail Bekker, Principal Investigator, Desmond Tutu HIV Centre, University of Cape Town
Margie McGlynn, President and CEO, IAVI

Scaled-up antiretroviral treatment (ART) and prevention reduced new HIV infections by more than one third over the past 10 years. Yet, in 2013, more than 35 million people lived with HIV, 2.1 million more became infected and 1.5 million died. Even if existing treatment and prevention options can be maximized, low- and middle-income countries will still see more than half a million new HIV infections a year come 2050, according to estimations as part of the UNAIDS enhanced investment framework.

A world without AIDS will require a vaccine and a cure. Researchers into both have long faced common challenges, including HIV’s variability, its direct attack on immune cells, and the limitations of animal models. But today, they are beginning to leverage common and critical developments that can help accelerate both vaccine and cure research. New optimism and confidence in both fields are emerging with a greater understanding of the immune responses needed to prevent and to control infection and of the role of ARVs, new technologies, and breakthrough results. Broadly neutralizing antibodies (bNAbs) capable of preventing infection have cleared SHIV in monkeys, raising hopes they could produce a similar effect in humans, potentially in combination with ART. Similarly, a vaccine aimed at inducing T-cell responses cleared SIV infection in some monkeys, suggesting that cellular immune responses could also be beneficial both prophylactically and therapeutically.

This session will explore the vaccine and cure landscape, the role of broadly neutralizing antibodies, T-cell and vector approaches in vaccine and cure research, and potential synergies in moving forward toward the end of AIDS.


Cure Research and Benefits of Enhanced Collaboration with Vaccine Research
Carl Dieffenbach, Director, Division of the AIDS (DAIDS) at the US National Institute of Allergy and Infectious Diseases (NIAID)

Vaccine Research and Benefits of Enhanced Collaboration with Cure Research
Wayne Koff, Chief Scientific Officer, IAVI

The Potential of Broadly Neutralizing Antibodies in Vaccine and Cure Research
John Mascola, Director, Vaccine Research Center (VRC) at the US National Institute of Allergy and Infectious Diseases (NIAID)

The Potential of T-cell and Vector Approaches in Vaccine and Cure Research
Louis Picker, Head, Division of Pathobiology and Immunology, Oregon Health & Science University

Q&A and refreshments following the presentations.